MIBI-Tc99m/Iodine-123

Radiopharmaceutical

NNantes University Hospital

MIBI-Tc99m/Iodine-123 is one of 6 small molecule programs targeting Thyroid Nodule. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid NoduleActive, not recruiting

Thyroid NodulePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Thyroid Nodule

#DrugCompanyPhaseTrials

Ethanol

Roche

Phase 1

1 2

Radioactive Iodine

UUniversity of Helsinki

Phase 3

1 3

Alcohol

Astellas

Phase 1

—4

Synthroid

IInstitut Jerome Lejeune

Preclinical

—5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

—6

MIBI-Tc99m/Iodine-123

NNantes University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Nodule1 trial

Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology

Completed·NNantes University Hospital·Phase 2/3·NCT03498183·372 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MIBI-Tc99m/Iodine-123. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MIBI-Tc99m/Iodine-123 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MIBI-Tc99m/Iodine-123. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nantes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Company: NNantes University Hospital

MIBI-Tc99m/Iodine-123

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Nodule1 trial

References

Drug Info

Quick Facts

Related News